Mark J. Gergen has been appointed senior vice president and chief operating officer at Halozyme Therapeutics, Inc. He reports to Dr. Helen Torley, president and chief executive officer. Mr. Gergen will be responsible for corporate development, including the management of Halozyme’s ENHANZE platform collaborations and overseeing the global product teams responsible for planning development and commercialization of its oncology pipeline, including clinical operations and clinical collabor...